Ernexa Therapeutics Inc. Other Nonrecurring Expense
Ernexa Therapeutics Inc. (ERNA) reported Other Nonrecurring Expense of $5.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherNonrecurringExpense · last filed 2026-05-11
- Ernexa Therapeutics Inc. other nonrecurring expense for the quarter ending 2026-03-31 was $5.30M, a 1.85% decline year-over-year.
- Ernexa Therapeutics Inc. other nonrecurring expense for the quarter ending 2025-12-31 was $500.00K.
- Ernexa Therapeutics Inc. other nonrecurring expense for the quarter ending 2025-09-30 was $700.00K, a 97.12% decline year-over-year.
- Ernexa Therapeutics Inc. other nonrecurring expense for the quarter ending 2025-06-30 was $600.00K, a 0.00% change year-over-year.
- Ernexa Therapeutics Inc. other nonrecurring expense for fiscal 2025 was $5.80M, a 74.34% decline from fiscal 2024.
- Ernexa Therapeutics Inc. other nonrecurring expense for fiscal 2024 was $22.60M.
- Ernexa Therapeutics Inc. other nonrecurring expense for fiscal 2023 was $0.00.
| Period end | Other Nonrecurring Expense 3 month | Other Nonrecurring Expense 6 month | Other Nonrecurring Expense 9 month | Other Nonrecurring Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $5.30M 10-Q · filed 2026-05-11 | $5.80M derived: sum of 2 quarters · filed 2026-05-11 | $6.50M derived: sum of 3 quarters · filed 2026-05-11 | $7.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.20M derived: sum of 2 quarters · filed 2026-03-13 | $1.80M derived: sum of 3 quarters · filed 2026-03-13 | $5.80M 10-K · filed 2026-03-13 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-11-07 | $1.30M derived: sum of 2 quarters · filed 2025-11-07 | $5.30M 10-Q · filed 2025-11-07 | $3.50M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-06-30 | $600.00K 10-Q · filed 2025-08-13 | $6.10M 10-Q · filed 2025-08-13 | $2.80M derived: sum of 3 quarters · filed 2026-03-13 | $27.10M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-03-31 | $5.40M 10-Q · filed 2025-05-07 | $2.20M derived: sum of 2 quarters · filed 2026-03-13 | $26.50M derived: sum of 3 quarters · filed 2026-03-13 | $27.10M derived: sum of 4 quarters · filed 2026-03-13 |
| 2024-12-31 | -$3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $21.10M derived: sum of 2 quarters · filed 2026-03-13 | $21.70M derived: sum of 3 quarters · filed 2026-03-13 | $22.60M 10-K · filed 2026-03-13 |
| 2024-09-30 | $24.30M 10-Q · filed 2025-11-07 | $24.90M derived: sum of 2 quarters · filed 2025-11-07 | $25.80M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-13 | $1.40M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |